# A Multicenter, Placebo-controlled, Double-blind Investigative Extension Trial of the Safety and Efficacy of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode

> **NCT00606177** · PHASE3 · COMPLETED · sponsor: **Otsuka Pharmaceutical Co., Ltd.** · enrollment: 99 (actual)

## Conditions studied

- Bipolar I Disorder

## Interventions

- **DRUG:** Aripiprazole
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00606177
- **Lead sponsor:** Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2014-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00606177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00606177, "A Multicenter, Placebo-controlled, Double-blind Investigative Extension Trial of the Safety and Efficacy of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode". Retrieved via AI Analytics 2026-08-23 from https://api.ai-analytics.org/clinical/NCT00606177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*